New hope for rare blood cancer: pacritinib trial opens
Disease control
Recruiting now
This study tests a drug called pacritinib in 30 people with Waldenström macroglobulinemia whose cancer returned or did not respond to prior treatment. The goal is to see if the drug can shrink tumors and improve symptoms. Participants take the drug by mouth and are monitored for …
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated May 13, 2026 15:58 UTC